Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tappei Takada

Showing results (131-140 of 153) with videos related to

Pageof 16
Sort By:
Human Cell|September 17, 2021
Increase of serum uric acid levels associated with APOE ε2 haplotype: a clinico-genetic investigation and in vivo approachMasatsune Ogura, Yu Toyoda, Masayuki Sakiyama, et al.
International Journal of Clinical Oncology|March 3, 2025
The first real-world evidence on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin followed by switch maintenance avelumab in advanced urothelial carcinoma: a propensity score-matched studySatoru Taguchi, Taketo Kawai, Yoshiaki Kurokawa, et al.
Japanese Journal of Clinical Oncology|January 15, 2025
Optimization of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy for Japanese patients with urothelial carcinomaTaketo Kawai, Yoshiaki Kurokawa, Satoru Taguchi, et al.
Human Cell|December 10, 2013
Common variant of leucine-rich repeat-containing 16A (LRRC16A) gene is associated with gout susceptibilityMasayuki Sakiyama, Hirotaka Matsuo, Seiko Shimizu, et al.
Scientific Reports|June 10, 2014
Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factorsAkiyoshi Nakayama, Hirotaka Matsuo, Hirofumi Nakaoka, et al.
The Journal of Biological Chemistry|February 27, 2026
SLC52A1 Is a Neofunctionalized Primate Urate Transporter Enabling Intestinal Urate SecretionSyunsuke Yamamoto, Katsuhisa Inoue, Tomoya Yasujima, et al.
Nature Communications|April 5, 2012
Decreased extra-renal urate excretion is a common cause of hyperuricemiaKimiyoshi Ichida, Hirotaka Matsuo, Tappei Takada, et al.
Antioxidants (Basel, Switzerland)|May 10, 2020
Higher Blood Uric Acid in Female Humans and Mice as a Protective Factor against Pathophysiological Decline of Lung FunctionHaruka Fujikawa, Yuki Sakamoto, Natsuki Masuda, et al.
Japanese Journal of Clinical Oncology|June 27, 2025
Predictive ability of the geriatric 8 screening tool for treatment completion of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy in patients with urothelial carcinomaYoshiaki Kurokawa, Taketo Kawai, Satoru Taguchi, et al.
Biomedicines|August 27, 2021
A Proposal for Practical Diagnosis of Renal Hypouricemia: Evidenced from Genetic Studies of Nonfunctional Variants of <i>URAT1/SLC22A12</i> among 30,685 Japanese IndividualsYusuke Kawamura, Akiyoshi Nakayama, Seiko Shimizu, et al.
Pageof 16

Showing results (131-140 of 153) with videos related to

Sort By:
Pageof 16
Human Cell|September 17, 2021
Increase of serum uric acid levels associated with APOE ε2 haplotype: a clinico-genetic investigation and in vivo approachMasatsune Ogura, Yu Toyoda, Masayuki Sakiyama, et al.
International Journal of Clinical Oncology|March 3, 2025
The first real-world evidence on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin followed by switch maintenance avelumab in advanced urothelial carcinoma: a propensity score-matched studySatoru Taguchi, Taketo Kawai, Yoshiaki Kurokawa, et al.
Japanese Journal of Clinical Oncology|January 15, 2025
Optimization of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy for Japanese patients with urothelial carcinomaTaketo Kawai, Yoshiaki Kurokawa, Satoru Taguchi, et al.
Human Cell|December 10, 2013
Common variant of leucine-rich repeat-containing 16A (LRRC16A) gene is associated with gout susceptibilityMasayuki Sakiyama, Hirotaka Matsuo, Seiko Shimizu, et al.
Scientific Reports|June 10, 2014
Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factorsAkiyoshi Nakayama, Hirotaka Matsuo, Hirofumi Nakaoka, et al.
The Journal of Biological Chemistry|February 27, 2026
SLC52A1 Is a Neofunctionalized Primate Urate Transporter Enabling Intestinal Urate SecretionSyunsuke Yamamoto, Katsuhisa Inoue, Tomoya Yasujima, et al.
Nature Communications|April 5, 2012
Decreased extra-renal urate excretion is a common cause of hyperuricemiaKimiyoshi Ichida, Hirotaka Matsuo, Tappei Takada, et al.
Antioxidants (Basel, Switzerland)|May 10, 2020
Higher Blood Uric Acid in Female Humans and Mice as a Protective Factor against Pathophysiological Decline of Lung FunctionHaruka Fujikawa, Yuki Sakamoto, Natsuki Masuda, et al.
Japanese Journal of Clinical Oncology|June 27, 2025
Predictive ability of the geriatric 8 screening tool for treatment completion of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy in patients with urothelial carcinomaYoshiaki Kurokawa, Taketo Kawai, Satoru Taguchi, et al.
Biomedicines|August 27, 2021
A Proposal for Practical Diagnosis of Renal Hypouricemia: Evidenced from Genetic Studies of Nonfunctional Variants of <i>URAT1/SLC22A12</i> among 30,685 Japanese IndividualsYusuke Kawamura, Akiyoshi Nakayama, Seiko Shimizu, et al.
Pageof 16